Lisata Therapeutics, Inc. · NASDAQ:LSTA

Lisata Therapeutics — Caladrius Biosciences — Merger or Acquisition (August 2022)

17 slides from Lisata Therapeutics's merger presentation, Aug 15, 2022

  1. Slide 1: The Evolution of Caladrius into Lisata

    David J. Mazzo, PhD President & Chief Executive Of f icer Au g u s t 15 , 2 0 2 2 | N a s da q : CL B S The Evolution of into Hello. This is David Mazzo, President and CEO of Caladrius Biosciences here to provide you with a summary of the information from the proxy statement/prospectus recently sent

  2. Slide 2: Information regarding disclosures: Forward-Looking Statements

    Information regarding disclosures Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statement

  3. Slide 3: Creating a new diversified therapeutics company, well-positioned for growth

    3 Creating a new diversified therapeutics company, well-positioned for growth (Nasdaq: LSTA) Merger targeted for shareholder approval on September 13, 2022  Name derived from the Finnish for “augmented” or “enhanced”  Diverse development pipeline, strong existing & potential for future additional

  4. Slide 4: Board composition of Lisata

    capitalization. Finally, Lisata’s board of directors will be comprised of 4 directors appointed by each side. 3

  5. Slide 5: Lisata Therapeutics overview

    Lisata Therapeutics overview  Experienced Executive and Development Leadership with extensive domain-relevant expertise  David J. Mazzo, Ph.D. – Chief Executive Officer  David Slack, M.B.A. – President and Chief Business Officer  Kristen K. Buck, M.D. – Executive Vice President of R&D and Chief

  6. Slide 6: Lisata projected to be financially sound

    Finally, Lisata is projected to be financially sound, with the ~$70 million of capital expected at closing anticipated to be sufficient to obviate the need for a capital raise for the foreseeable future. 4

  7. Slide 7: Lisata Therapeutics strategic rationale: platform technologies

    Lisata Therapeutics strategic rationale 5 CendR Platform™ provides a targeted tissue penetration capability designed to specifically enhance drug delivery to solid tumors  Converts tumor stroma from barrier to conduit for effective delivery via co-administration of a range of chemo-, targeted and i

  8. Slide 8: Platform technologies and patent protection

    Therapy Platform with ongoing development programs advancing to their next development milestone. All the Lisata platform technologies have patent protection beyond 2030 plus patent term extension eligibility. 5

  9. Slide 9: Lisata Therapeutics strategic rationale: lead candidate CEND-1

    Lisata Therapeutics strategic rationale 6 Lead product candidate, CEND-1, advancing in a variety of difficult-to-treat solid tumor applications  CEND-1 is currently in multiple studies in first-line, metastatic pancreatic ductal adenocarcinoma (mPDAC) in combination with standard-of-care chemothera

  10. Slide 10: Upcoming milestones for HONEDRA and CLBS201

    end, the continuation of the HONEDRA® pre-consultation/consultation process with Japanese Regulatory Authorities and the availability of CLBS201 proof-of-concept results expected in 1Q2023. 6

  11. Slide 11: Lisata Therapeutics strategic rationale: partnerships

    Lisata Therapeutics strategic rationale 7  Existing Cend strategic partnership in China with Qilu Pharmaceutical with non-dilutive milestone payments, development collaboration, and participation in downstream economics  Potential for up to $225 million in milestones and royalties on potential sal

  12. Slide 12: Business development milestones over the next months

    business development milestones over the next 24 months. 7

  13. Slide 13: Lisata pipeline by sponsor, trial and phase

    Sponsor/Funding Institution Trial Products Indication Preclinical Phase 1 Phase 2 Phase 3 CendR Programs Lisata (U.S.) Ph2/3 adaptive Gemcitabine/nab-paclitaxel ± CEND-1 First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) SWOG - NCI (U.S.) Ph2/3 FOLFIRINOX ± CEND-1 AGITG (Aus) Ph2b Gemcit

  14. Slide 14: Lisata Therapeutics anticipated milestones

    Lisata Therapeutics anticipated milestones 9 2022 2023 2024 CEND-1 Ph2b in mPDAC (Aus) initiated 2Q 2022 CEND-1 Ph1b/2 in mPDAC + Atezolizumab (Roche; multi- national) initiation 4Q 2022 CEND-1 Ph1b/2 in mPDAC (Qilu; China) preliminary data target 1H 2023 CEND-1 Ph2a solid tumor basket trial initiat

  15. Slide 15: Merger process mechanics: What we need Caladrius shareholders to do

    Merger process mechanics: What we need Caladrius shareholders to do  Proxy Statement (description of the proposed merger) has been sent to all shareholders of record  Announces the Annual Meeting of Shareholders at which the merger & related matters will be considered  The Annual Meeting of Share

  16. Slide 16: Timeline of the transaction

    Timeline of the transaction 11  Caladrius and Cend Announced Definitive Merger Agreement  Filing of S-4 Related to the Proposed Merger with Cend Therapeutics  Record Date for determining eligibility of shares to be voted  Mailing date of Proxy Statement to Shareholders  Annual Meeting of Shareh

  17. Slide 17: Investor Relations Contact

    Investor Relations Contact: John D. Menditto Tel: (908) 842-0084 jmenditto@caladrius.com Au g u s t 15 , 2 0 2 2 | N a s da q : CL B S Upon merger closing, to become: As always, we thank our shareholders for their support and look forward to sharing in the successes of Lisata Therapeutics in the fut

Caladrius Biosciences — Merger or Acquisition (August 2022) on 6ix